Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,748 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01484080 | Neoadjuvant Paclitaxel Versus BIBF 1120 Priming Followed by BIBF 1120 Plus Paclitaxel in Early HER-2 Negative Breast Cancer With Proteomic and Dynamic Imaging Correlates | completed | Phase 1 / Phase 2 | 140 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Jan 27, 2020 | clinicaltrials |
| NCT02383212 | Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies | completed | Phase 1 | 398 | Regeneron PharmaceuticalsINDUSTRY | 3 | Jan 27, 2020 |
| clinicaltrials |
| NCT02264418 | Safety and Tolerability of ODM-203 in Subjects With Advanced Solid Tumours(KIDES-203) | completed | Phase 1 | 84 | Orion Corporation, Orion PharmaINDUSTRY | 6 | Jan 18, 2020 | clinicaltrials |
| NCT02350673 | A Study of Intravenous (IV) Cergutuzumab Amunaleukin and Atezolizumab in Combination in Participants With Locally Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 70 | Hoffmann-La RocheINDUSTRY | 6 | Jan 18, 2020 | clinicaltrials |
| NCT02340936 | Clinical Trial to Determinate Dose, Security and Efficacy or Lenalidomide and Rituximab (LR)-ESHAP in Patients With Diffuse Large B-cell Lymphoma | completed | Phase 1 / Phase 2 | 53 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Jan 10, 2020 | clinicaltrials |
| NCT01583777 | Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced Cancer | completed | Phase 1 | 6 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 3, 2020 | clinicaltrials |
| NCT01962103 | Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 107 | CelgeneINDUSTRY | 7 | Dec 27, 2019 | clinicaltrials |
| NCT02014116 | A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body | terminated | Phase 1 | 51 | Eli Lilly and CompanyINDUSTRY | 4 | Dec 27, 2019 | clinicaltrials |
| NCT02304393 | A Study of Selicrelumab (RO7009789) in Combination With Atezolizumab in Participants With Locally Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 140 | Hoffmann-La RocheINDUSTRY | 6 | Dec 13, 2019 | clinicaltrials |
| NCT02034123 | Investigation of GSK2879552 in Subjects With Relapsed/Refractory Small Cell Lung Carcinoma | terminated | Phase 1 | 29 | GlaxoSmithKlineINDUSTRY | 3 | Dec 6, 2019 | clinicaltrials |
| NCT03301207 | A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancy | completed | Phase 1 | 25 | Janssen Research & Development, LLCINDUSTRY | 2 | Dec 5, 2019 | clinicaltrials |
| NCT02548962 | Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma | terminated | Phase 1 / Phase 2 | 11 | Pharmacyclics LLC.INDUSTRY | 6 | Nov 21, 2019 | clinicaltrials |
| NCT03023423 | A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer(DARZALEX) | completed | Phase 1 / Phase 2 | 100 | Janssen Research & Development, LLCINDUSTRY | 5 | Nov 20, 2019 | clinicaltrials |
| NCT01478685 | A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors | completed | Phase 1 | 169 | CelgeneINDUSTRY | 4 | Nov 12, 2019 | clinicaltrials |
| NCT01545947 | Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer | completed | Phase 1 | 76 | CelgeneINDUSTRY | 2 | Nov 12, 2019 | clinicaltrials |
| NCT00419250 | A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia | completed | Phase 1 | 52 | CelgeneINDUSTRY | 7 | Nov 8, 2019 | clinicaltrials |
| NCT02000947 | A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer(D4190C00006) | completed | Phase 1 | 459 | MedImmune LLCINDUSTRY | 9 | Oct 31, 2019 | clinicaltrials |
| NCT01899053 | A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies | completed | Phase 1 | 101 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Oct 30, 2019 | clinicaltrials |
| NCT02448251 | Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer | terminated | Phase 1 | 28 | ACEA Therapeutics, Inc.INDUSTRY | 3 | Oct 29, 2019 | clinicaltrials |
| NCT02471846 | A Study of GDC-0919 and Atezolizumab Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 158 | Genentech, Inc.INDUSTRY | 4 | Oct 22, 2019 | clinicaltrials |
| NCT01004224 | A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies | completed | Phase 1 | 208 | Novartis PharmaceuticalsINDUSTRY | 14 | Oct 4, 2019 | clinicaltrials |
| NCT02711345 | A Phase I Clinical Study With Investigational Compound LTT462 in Adult Patients With Specific Advanced Cancers. | terminated | Phase 1 | 65 | Novartis PharmaceuticalsINDUSTRY | 6 | Sep 19, 2019 | clinicaltrials |
| NCT02745743 | Phase I Trial of BAY1251152 for Advanced Blood Cancers | completed | Phase 1 | 21 | BayerINDUSTRY | 4 | Sep 19, 2019 | clinicaltrials |
| NCT02876224 | Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors | completed | Phase 1 | 51 | Hoffmann-La RocheINDUSTRY | 2 | Aug 13, 2019 | clinicaltrials |
| NCT02783599 | A Study of Olaratumab (LY3012207) in Participants With Soft Tissue Sarcoma | completed | Phase 1 | 51 | Eli Lilly and CompanyINDUSTRY | 5 | Aug 12, 2019 | clinicaltrials |
| NCT02194426 | First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients | completed | Phase 1 / Phase 2 | 58 | Molecular Partners AGINDUSTRY | 3 | Aug 7, 2019 | clinicaltrials |
| NCT02734160 | A Study of Galunisertib (LY2157299) and Durvalumab (MEDI4736) in Participants With Metastatic Pancreatic Cancer | completed | Phase 1 | 37 | Eli Lilly and CompanyINDUSTRY | 5 | Aug 5, 2019 | clinicaltrials |
| NCT03065023 | Study of Intralesional Administration of MK-4621 (RGT100) in Adult Participants With Advanced or Recurrent Tumors (MK-4621-001/RGT100-001) | terminated | Phase 1 / Phase 2 | 15 | Merck Sharp & Dohme LLCINDUSTRY | 3 | Jul 30, 2019 | clinicaltrials |
| NCT02069704 | Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients | completed | Phase 1 | 142 | mAbxience Research S.L.INDUSTRY | 5 | Jul 23, 2019 | clinicaltrials |
| NCT02619162 | Nintedanib+Letrozole in Postmenopausal Women With Breast Cancer: Clinical Trial Safety and Pharmacodynamics | completed | Phase 1 | 25 | Centro Nacional de Investigaciones Oncologicas CARLOS IIIOTHER | 1 | Jul 23, 2019 | clinicaltrials |
| NCT01853228 | A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 17 | Janssen Research & Development, LLCINDUSTRY | 7 | Jun 17, 2019 | clinicaltrials |
| NCT02665650 | Study of the Combination of AFM13 and Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 1 | 30 | Affimed GmbHINDUSTRY | 2 | May 16, 2019 | clinicaltrials |
| NCT02243436 | Brentuximab Vedotin in Pre-transplant Induction and Consolidation for Relapsed or Refractory Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 67 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Apr 24, 2019 | clinicaltrials |
| NCT02565758 | ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors | completed | Phase 1 | 85 | AbbVieINDUSTRY | 3 | Apr 5, 2019 | clinicaltrials |
| NCT02048488 | A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas | completed | Phase 1 / Phase 2 | 72 | Tesaro, Inc.INDUSTRY | 5 | Mar 26, 2019 | clinicaltrials |
| NCT02568046 | Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients | terminated | Phase 1 / Phase 2 | 10 | Symphogen A/SINDUSTRY | 2 | Mar 26, 2019 | clinicaltrials |
| NCT01231594 | A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors | completed | Phase 1 | 214 | Novartis PharmaceuticalsINDUSTRY | 9 | Mar 22, 2019 | clinicaltrials |
| NCT02723877 | PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) | completed | Phase 1 / Phase 2 | 41 | PIQUR Therapeutics AGINDUSTRY | 2 | Mar 22, 2019 | clinicaltrials |
| NCT00651664 | A Phase I Clinical and Pharmacodynamic Study of MLN8237, A Novel Aurora A Kinase Inhibitor, in Participants With Advanced Malignancies | completed | Phase 1 | 59 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 15, 2019 | clinicaltrials |
| NCT00979134 | Study is Designed to Assess the Safety and Tolerability of AZD4547 at Increasing Doses in Patients With Advanced Tumours | terminated | Phase 1 | 95 | AstraZenecaINDUSTRY | 7 | Mar 15, 2019 | clinicaltrials |
| NCT01283516 | A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase | completed | Phase 1 | 304 | Novartis PharmaceuticalsINDUSTRY | 11 | Mar 15, 2019 | clinicaltrials |
| NCT01876251 | A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer | terminated | Phase 1 | 30 | PfizerINDUSTRY | 4 | Mar 15, 2019 | clinicaltrials |
| NCT02161770 | Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment | completed | Phase 1 | 30 | AstraZenecaINDUSTRY | 6 | Mar 8, 2019 | clinicaltrials |
| NCT01136733 | A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment | completed | Phase 1 / Phase 2 | 173 | Eisai Inc.INDUSTRY | 5 | Feb 27, 2019 | clinicaltrials |
| NCT02205398 | Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy | terminated | Phase 1 | 13 | Novartis PharmaceuticalsINDUSTRY | 7 | Jan 22, 2019 | clinicaltrials |
| NCT03792724 | Phase I-II Study of Intratumoral Urelumab Combined With Nivolumab in Patients With Solid Tumors(INTRUST) | unknown | Phase 1 / Phase 2 | 32 | Clinica Universidad de Navarra, Universidad de NavarraOTHER | 1 | Jan 3, 2019 | clinicaltrials |
| NCT02454270 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies | terminated | Phase 1 | 59 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 20, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials